For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next five years. New specific and sensitive markers of hemostasis will be increasingly used on automated instrumentation. Coagulation testing in general, and Thrombin Time testing specifically, will become more standardized, offering opportunities for quality control products and services. Moreover, the continuing contraction of the hospital system and technological advances will facilitate decentralization of the Thrombin Time testing closer to the patient, creating additional opportunities and challenges for suppliers.
This report presents a detailed analysis of the Thrombin Time testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice, as well as 5-year test volume forecasts by country and market segment.
The report examines market applications of chromogenic substrates, monoclonal antibodies, immunoassays, IT, DNA probes, biochips/microarrays, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks.Contains 196 pages and 8 tables